Mirae Asset Global Investments
CHRS icon

Mirae Asset Global Investments’s Coherus Oncology CHRS Stock Holding History

Mirae Asset Global Investments’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2K Buy
7,796
+1,922
+33% +$3.41K ﹤0.01% 1474
2025
Q4 		$8.34K Buy
+5,874
New +$8.56K ﹤0.01% 1610
2024
Q4 		– Sell
-4,167
Closed -$4.38K – 1605
2024
Q3 		$4.38K Buy
4,167
+742
+22% +$1.02K ﹤0.01% 1523
2024
Q2 		$5.82K Sell
3,425
-41,723
-92% -$84K ﹤0.01% 1488
2024
Q1 		$277K Buy
+45,148
New +$111K ﹤0.01% 2142
2023
Q4 		– Sell
-72,241
Closed -$270K – 2539
2023
Q3 		$270K Buy
72,241
+28,272
+64% +$131K ﹤0.01% 2177
2023
Q2 		$188K Sell
43,969
-14,966
-25% -$88.3K ﹤0.01% 2365
2023
Q1 		$403K Buy
58,935
+15,125
+35% +$117K ﹤0.01% 2029
2022
Q4 		$347K Buy
43,810
+28
+0.1% +$215 ﹤0.01% 2078
2022
Q3 		$421K Buy
43,782
+23,530
+116% +$238K ﹤0.01% 1971
2022
Q2 		$146K Buy
+20,252
New +$176K ﹤0.01% 2235
2021
Q3 		– Sell
-102,449
Closed -$1.42M – 1744
2021
Q2 		$1.42M Sell
102,449
-14,193
-12% -$201K ﹤0.01% 1157
2021
Q1 		$1.7M Sell
116,642
-5,198
-4% -$88.3K 0.01% 985
2020
Q4 		$2.12M Sell
121,840
-198
-0.2% -$3.52K 0.01% 913
2020
Q3 		$2.28M Buy
122,038
+40,924
+50% +$761K 0.01% 756
2020
Q2 		$1.45M Sell
81,114
-37,556
-32% -$636K 0.01% 793
2020
Q1 		$1.93M Sell
118,670
-50,181
-30% -$927K 0.02% 656
2019
Q4 		$3.04M Sell
168,851
-55,461
-25% -$1.02M 0.02% 625
2019
Q3 		$4.54M Sell
224,312
-77,363
-26% -$1.55M 0.03% 489
2019
Q2 		$6.67M Buy
301,675
+194
+0.1% +$3.37K 0.05% 397
2019
Q1 		$4.11M Buy
301,481
+10,794
+4% +$144K 0.03% 459
2018
Q4 		$2.63M Sell
290,687
-84,985
-23% -$983K 0.02% 531
2018
Q3 		$6.2M Buy
375,672
+46,528
+14% +$825K 0.05% 368
2018
Q2 		$4.61M Buy
+329,144
New +$4.71M 0.06% 190

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Mirae Asset Global Investments's CHRS Position: Q1 2026 in Review

Mirae Asset Global Investments increased its Coherus Oncology (CHRS) stake by 33% in Q1 2026, buying an estimated $3.41K and bringing the position to 7,796 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1474.

Mirae Asset Global Investments first reported a position in CHRS in Q2 2018 and has held it in 24 quarters since. The position peaked at $6.67M in Q2 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Mirae Asset Global Investments held 7,796 shares of Coherus Oncology worth $13.2K as of Q1 2026.
  • Mirae Asset Global Investments bought 1,922 Coherus Oncology shares in Q1 2026, an estimated $3.41K.
  • Coherus Oncology made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q1 2026, its #1474 holding.
  • Mirae Asset Global Investments first reported a position in Coherus Oncology in Q2 2018 and has held it in 24 quarters since.
  • Mirae Asset Global Investments's Coherus Oncology position peaked at $6.67M in Q2 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Mirae Asset Global Investments's 13F filing for Q1 2026, filed 4 May 2026.